Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-Early Response Hepatitis B e Antigen-Positive Patients.

ABSTRACT:

Background

The efficacy of nucleot(s)ide analogs (NAs) and pegylated interferon (PegIFN) combination therapy for hepatitis B e antigen-positive (HBeAg⁺) patients is still controversial. Whether PegIFN and entecavir (ETV) combination therapy could provide a greater benefit for HBeAg⁺ patients was assessed.

Methods

Treatment-naïve HBeAg⁺ patients initiated on PegIFN alfa-2a (PegIFNα-2a) for 24 weeks without early response (early response: HBsAg <1500 IU/mL and hepatitis B virus [HBV] DNA <10⁵ copies/mL) were recruited in the current study. Among total of 94 patients, 51 were continued on PegIFNα-2a monotherapy, and 43 were offered PegIFNα-2a and ETV combined therapy.

Results

Better outcomes in response to the combined therapy,

SUBMITTER: Chen L 

PROVIDER: S-EPMC8050793 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature